Table 2.
Study reviewed | NRT treatment given | Blood nicotine concentrations | Safety conclusions |
Foulds et al, 1992 | 16+ cigarettes per day (cpd) & 15 milligram (mg) transdermal patch (TP) over 16 hrs | Baseline: 37 nanograms per millilitre (ng/ml), Placebo: 36 ng/ml, 15 mg TP: 44 ng/ml. | Participants experienced almost no subjective toxic effects whilst wearing the patch |
Pickworth, Bunker & Henningfield, 1994 | 13+ cpd & 22 mg, 44 mg TP over 24 hrs | Baseline: 30 ng/ml, Placebo: 19 ng/ml, 22 mg TP: 39 ng/ml, 44 mg TP: 63 ng/ml. |
No adverse subjective experiences were reported. |
Mahmarian et al, 1997 | 8+ cpd & 14 mg TP over 24 hrs | Baseline 16 ng/ml, 14 mg TP: 24 ng/ml, 21 mg TP: 30 ng/ml. | Only adverse effects noted were nausea & vomiting in 2 patients. |
Zevin, Jacob & Benowitz, 1998 | Smoking ad libitum & 21 mg, 42 mg, 63 mg patch over 8 hours | Placebo: 20 ng/ml, 63 mg TP: 60 ng/ml. | No additional haemodynamic effects of TP on heart rate, blood pressure, noradrenaline, white blood cell count, fibrinogen, haematocrit, cortisol, or lipids. No adverse reactions. |
Carpenter et al, 2000 | 11+ cpd & TP, gum or inhaler | Lower than 22 mg TP: 54% increase, Higher than 22 mg TP: 190% increase. | Number of cpd reduced by 43% and CO by 31%. |